DK2344253T3 - Anvendelse af histon-deacetylase-inhibitorer til pleje af philadelphia-negative myeloproliferative syndromer - Google Patents

Anvendelse af histon-deacetylase-inhibitorer til pleje af philadelphia-negative myeloproliferative syndromer

Info

Publication number
DK2344253T3
DK2344253T3 DK09783251.3T DK09783251T DK2344253T3 DK 2344253 T3 DK2344253 T3 DK 2344253T3 DK 09783251 T DK09783251 T DK 09783251T DK 2344253 T3 DK2344253 T3 DK 2344253T3
Authority
DK
Denmark
Prior art keywords
philadelphia
care
deacetylase inhibitors
histon deacetylase
myeloproliferative syndromes
Prior art date
Application number
DK09783251.3T
Other languages
English (en)
Inventor
Tiziano Oldoni
Paolo Mascagni
Tiziano Barbui
Alessandro Rambaldi
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Application granted granted Critical
Publication of DK2344253T3 publication Critical patent/DK2344253T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK09783251.3T 2008-09-29 2009-09-21 Anvendelse af histon-deacetylase-inhibitorer til pleje af philadelphia-negative myeloproliferative syndromer DK2344253T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2008A001720A IT1392908B1 (it) 2008-09-29 2008-09-29 Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative
US19328308P 2008-11-13 2008-11-13
PCT/EP2009/062214 WO2010034693A1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Publications (1)

Publication Number Publication Date
DK2344253T3 true DK2344253T3 (da) 2014-06-16

Family

ID=40810309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09783251.3T DK2344253T3 (da) 2008-09-29 2009-09-21 Anvendelse af histon-deacetylase-inhibitorer til pleje af philadelphia-negative myeloproliferative syndromer

Country Status (17)

Country Link
US (4) US20110294892A1 (da)
EP (1) EP2344253B1 (da)
JP (1) JP2012504112A (da)
KR (3) KR20170124640A (da)
CN (1) CN102164638A (da)
BR (1) BRPI0913699A2 (da)
CA (1) CA2738081C (da)
CY (1) CY1115255T1 (da)
DK (1) DK2344253T3 (da)
ES (1) ES2478827T3 (da)
HR (1) HRP20140499T1 (da)
IT (1) IT1392908B1 (da)
PL (1) PL2344253T3 (da)
PT (1) PT2344253E (da)
SI (1) SI2344253T1 (da)
SM (1) SMT201400087B (da)
WO (1) WO2010034693A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
US20180127386A1 (en) 2016-10-20 2018-05-10 Forma Therapeutics, Inc. Methods using hdac11 inhibitors
US10865328B2 (en) * 2017-02-20 2020-12-15 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US20080194681A1 (en) * 2004-12-09 2008-08-14 Kalypsys, Inc. Novel Inhibitors of Histone Deacetylase for the Treatment of Disease
AR056682A1 (es) * 2005-07-29 2007-10-17 Kalypsys Inc COMPUESTOS MULTICíCLICOS DERIVADOS DE LA SULFONAMIDA COMO INHIBIDORES DE LA HISTONA DESACETILASA Y COMPOSICIoN FARMACÉUTICA
CN101426903A (zh) 2005-12-09 2009-05-06 麻省理工学院 基于细胞核形态鉴定并靶向肿瘤干细胞的方法
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2008082646A2 (en) * 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Also Published As

Publication number Publication date
SMT201400087B (it) 2014-09-08
KR20110069075A (ko) 2011-06-22
WO2010034693A1 (en) 2010-04-01
US20210128512A1 (en) 2021-05-06
CA2738081C (en) 2017-11-07
EP2344253B1 (en) 2014-04-23
PT2344253E (pt) 2014-07-16
US20170049740A1 (en) 2017-02-23
EP2344253A1 (en) 2011-07-20
SI2344253T1 (sl) 2014-08-29
US20110294892A1 (en) 2011-12-01
CA2738081A1 (en) 2010-04-01
ES2478827T3 (es) 2014-07-23
US20140039059A1 (en) 2014-02-06
IT1392908B1 (it) 2012-04-02
ITMI20081720A1 (it) 2010-03-30
KR20160096721A (ko) 2016-08-16
JP2012504112A (ja) 2012-02-16
CY1115255T1 (el) 2017-01-04
CN102164638A (zh) 2011-08-24
HRP20140499T1 (hr) 2014-07-04
KR20170124640A (ko) 2017-11-10
US9522127B2 (en) 2016-12-20
BRPI0913699A2 (pt) 2017-06-13
PL2344253T3 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
LTC3078743I2 (lt) Antikūnai xa veiksnio inhibitoriams ir jų naudojimo būdai
DK2776048T3 (da) Farmaceutiske sammensætninger indeholdende pediococcus og fremgangsmåder til at reducere symptomerne af gastroenterologiske syndromer
DK2379600T4 (da) Antistoffer mod tissue factor pathway inhibitor
DK3338799T3 (da) Antistoffer til il-6 og anvendelse deraf
DK2498756T3 (da) Tabletformuleringer af neratinibmaleat
DK2616064T3 (da) Ketorolacformuleringer klar til anvendelse
DK3226459T3 (da) Udveksling af parametre relateret til måleperioder
DK3045043T3 (da) Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
DK2449057T3 (da) Fremgangsmåde til omdannelse af lignocellulosematerialer til anvendelige kemikalier
DK1996292T3 (da) Anvendelse af peptider til bekæmpelse af stråleskade
DK2663864T3 (da) Fremgangsmåde til at vurdere immundiversitet og anvendelse af denne
DK2346509T3 (da) Inhalation af levofloxacin til at reducere lungeinflammation
BR112012026855A2 (pt) método para simultaneamente limpar e branquear limpar e branquear dentes
DK2616035T3 (da) Indretning til at hjælpe med at gå med støtte
DK2421537T3 (da) Pyrazolylaminopyridiner som inhibitorer af FAK
DK2117564T3 (da) Anvendelse af chitosaner til forøgelse af neglevæksthastigheden
DK2506840T3 (da) Anvendelser af hæmmere af hypoksi-fremkaldende faktorer
DK2143429T5 (da) Anvendelse af cilastatin til reduktion af nephrotoksicitet af forskellige forbindelser
DK2539310T3 (da) Syntese af magnolol og dets analogforbindelser
DK2344253T3 (da) Anvendelse af histon-deacetylase-inhibitorer til pleje af philadelphia-negative myeloproliferative syndromer
DK2310018T3 (da) Anvendelse af nifurtimox til behandling af giardiasis
DK2173197T3 (da) Fremgangsmåde
DK2523911T3 (da) Bærerindsats til at rumme og opretholde biofilmkulturen af rensningsstrukturer
DK2407155T3 (da) Formuleringer af inecalcitol
SMT201500123B (it) Dosaggio unitario di apadenoson